Developing Combination Therapy Strategies for Ovarian Cancer

March 1, 2018
Kathleen Moore, MD

Kathleen Moore, MD, associate director for clinical research at the Stephenson Oklahoma Cancer Center, discusses the development of combination therapy strategies for patients with ovarian cancer.

Kathleen Moore, MD, associate director for clinical research at the Stephenson Oklahoma Cancer Center, discusses the development of combination therapy strategies for patients with ovarian cancer.

Immunotherapy combinations are currently being tested in many clinical trials for patients with ovarian cancer. Moore says immune agents are being combined with antiangiogenic agents, PARP inhibitors, cytotoxic chemotherapy, as well as other immune agents.